株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Grunenthal GmbH - 製品パイプラインレビュー

Grunenthal GmbH - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 219819
出版日 ページ情報 英文 47 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
Grunenthal GmbH - 製品パイプラインレビュー Grunenthal GmbH - Product Pipeline Review - 2016
出版日: 2016年07月30日 ページ情報: 英文 47 Pages
概要

Grunenthal GmbH は研究に主眼を置く、世界規模の製薬会社です。特に疼痛治療と、実証済みの有効成分を革新的な手法で処方することにかけて長け、疼痛治療薬を開発・製造・販売しています。

当レポートでは、Grunenthal GmbHにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Grunenthal GmbHの基本情報

Grunenthal GmbHの概要

  • 主要情報
  • 企業情報

Grunenthal GmbH:R&Dの概要

  • 主な治療範囲

Grunenthal GmbH:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Grunenthal GmbH:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Grunenthal GmbH:開発段階が不明のパイプライン製品

  • 開発段階が不明の製品/併用療法モダリティ

Grunenthal GmbH:薬剤プロファイル

  • cebranopadol
  • tapentadol hydrochloride
  • tapentadol hydrochloride ER
  • GRT-6010
  • GRT-6011
  • Small Molecule 1 for Pain
  • Small Molecule 2 for Pain
  • GRTTA-2210
  • RO-656570
  • Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation
  • Small Molecule-3 for Pain
  • Small Molecule for Pain
  • (oxycodone + naloxone)
  • GRT-6006

Grunenthal GmbH:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Grunenthal GmbH:最近のパイプライン動向

Grunenthal GmbH:休止中のプロジェクト

Grunenthal GmbH:企業発表

Grunenthal GmbH:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08104CDB

Summary

Global Markets Direct's, 'Grunenthal GmbH - Product Pipeline Review - 2016', provides an overview of the Grunenthal GmbH's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Grunenthal GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Grunenthal GmbH
  • The report provides overview of Grunenthal GmbH including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Grunenthal GmbH's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Grunenthal GmbH's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Grunenthal GmbH's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Grunenthal GmbH
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Grunenthal GmbH's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Grunenthal GmbH Snapshot
    • Grunenthal GmbH Overview
    • Key Information
    • Key Facts
  • Grunenthal GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • Grunenthal GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Grunenthal GmbH - Pipeline Products Glance
    • Grunenthal GmbH - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Grunenthal GmbH - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Grunenthal GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Grunenthal GmbH - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Grunenthal GmbH - Drug Profiles
    • cebranopadol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tapentadol hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GRTTA-2210
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RO-656570
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 3 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate KCNQ and TSPO for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Grunenthal GmbH - Pipeline Analysis
    • Grunenthal GmbH - Pipeline Products by Target
    • Grunenthal GmbH - Pipeline Products by Route of Administration
    • Grunenthal GmbH - Pipeline Products by Molecule Type
    • Grunenthal GmbH - Pipeline Products by Mechanism of Action
  • Grunenthal GmbH - Recent Pipeline Updates
  • Grunenthal GmbH - Dormant Projects
  • Grunenthal GmbH - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • axomadol
      • lexanopadol
  • Grunenthal GmbH - Company Statement
  • Grunenthal GmbH - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Grunenthal GmbH, Key Information
  • Grunenthal GmbH, Key Facts
  • Grunenthal GmbH - Pipeline by Indication, 2016
  • Grunenthal GmbH - Pipeline by Stage of Development, 2016
  • Grunenthal GmbH - Monotherapy Products in Pipeline, 2016
  • Grunenthal GmbH - Partnered Products in Pipeline, 2016
  • Grunenthal GmbH - Partnered Products/ Combination Treatment Modalities, 2016
  • Grunenthal GmbH - Phase III, 2016
  • Grunenthal GmbH - Phase II, 2016
  • Grunenthal GmbH - Phase I, 2016
  • Grunenthal GmbH - Preclinical, 2016
  • Grunenthal GmbH - Discovery, 2016
  • Grunenthal GmbH - Unknown, 2016
  • Grunenthal GmbH - Pipeline by Target, 2016
  • Grunenthal GmbH - Pipeline by Route of Administration, 2016
  • Grunenthal GmbH - Pipeline by Molecule Type, 2016
  • Grunenthal GmbH - Pipeline Products by Mechanism of Action, 2016
  • Grunenthal GmbH - Recent Pipeline Updates, 2016
  • Grunenthal GmbH - Dormant Developmental Projects,2016
  • Grunenthal GmbH - Discontinued Pipeline Products, 2016
  • Grunenthal GmbH, Other Locations
  • Grunenthal GmbH, Subsidiaries

List of Figures

  • Grunenthal GmbH - Pipeline by Top 10 Indication, 2016
  • Grunenthal GmbH - Pipeline by Stage of Development, 2016
  • Grunenthal GmbH - Monotherapy Products in Pipeline, 2016
  • Grunenthal GmbH - Partnered Products in Pipeline, 2016
  • Grunenthal GmbH - Pipeline by Target, 2016
  • Grunenthal GmbH - Pipeline by Route of Administration, 2016
  • Grunenthal GmbH - Pipeline by Molecule Type, 2016
  • Grunenthal GmbH - Pipeline Products by Mechanism of Action, 2016
Back to Top